Synaptogenix Inc (SNPX)

[runncoach]

I'm not sure about the 1st trial but without looking at the 2nd I think the 2nd was way under 22%. Of course a trial twice as long stands to reason a few more may drop out. Then again some of it depends on severity of the disease most likely too. I would expect fewer to drop out of this trial for us than the last trial which already had a low number.